Modecate Injection 25mg/mlClick here for US version. Every effort has been made to epi tren before and after that the information provided here is accurate, up-to-date and wffects, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been modecate depot injection side effects for use by healthcare practitioners and consumers in the United States. The absence of a warning for a kodecate drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient.
MODECATE INJECTION 25MG/ML | carinsurancequote1k.top
Click here for US version. Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States.
The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient.
If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Subscribe to receive email notifications whenever new articles are published. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
To view content sources and attributions, please refer to our editorial policy. We comply with the HONcode standard for trustworthy health information - verify here. Also contains sesame oil q. For full list of excipients, see section 6. While Modecate injection has been shown to be effective in acute states, it is particularly useful in the maintenance treatment of chronic patients who are unreliable at taking their oral medication, and also of those who do not absorb their oral phenothiazine adequately.
Recommended dosage regimes for all indications: Patients without previous exposure to a depot fluphenazine formulation: The onset of action generally appears between 24 and 72 hours after injection and the effects of the drug on psychotic symptoms become significant within 48 to 96 hours.
When administered as maintenance therapy, a single injection may be effective in controlling schizophrenic symptoms for up to four weeks or longer. It is desirable to maintain as much flexibility in the dose as possible to achieve the best therapeutic response with the least side-effects; most patients are successfully maintained within the dose range 0. Patients previously maintained on oral fluphenazine: It is not possible to predict the equivalent dose of depot formulation in view of the wide variability of individual response.
Patients previously maintained on depot fluphenazine: Patients who have suffered a relapse following cessation of depot fluphenazine therapy may be restarted on the same dose, although the frequency of injections may need to be increased in the early weeks of treatment until satisfactory control is obtained. Elderly patients may be particularly susceptible to extrapyramidal reactions, sedative and hypotensive effects.
In order to avoid this, a reduced maintenance dosage may be required and a smaller initial dose see above. Not recommended for children. Note The dosage should not be increased without close supervision and it should be noted that there is a variability in individual response. The response to antipsychotic drug treatment may be delayed. If drugs are withdrawn, recurrence of symptoms may not become apparent for several weeks or months. Liver disease Renal impairment Cardiac arrhythmias, cardiac disease Thyrotoxicosis Severe respiratory disease Epilepsy, conditions predisposing to epilepsy e.
Cases of venous thromboembolism VTE have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with fluphenazine and preventative measures undertaken.
Acute withdrawal symptoms, including nausea, vomiting, sweating and insomnia have been described after abrupt cessation of antipsychotic drugs. Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders such as akathisia, dystonia and dyskinesia has been reported.
Therefore, gradual withdrawal is advisable. Psychotic patients on large doses of phenothiazines who are undergoing surgery should be watched carefully for hypotension. Reduced amounts of anaesthetics or central nervous system depressants may be necessary. Fluphenazine should be used with caution in patients exposed to organophosphorus insecticides Neuroleptic drugs elevate prolactin levels, and an increase in mammary neoplasms has been found in rodents after chronic administration.
However, studies to date have not shown an association between chronic administration of these drugs and human mammary tumours. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known. Fluphenazine is not licensed for the treatment of dementia-related behavioural disturbances.
Modecate contains benzyl alcohol as a preservative and must not be given to premature babies or neonates. The administration of medicines containing benzyl alcohol as a preservative may cause toxic reactions and anaphylactoid reactions in children up to 3 years old.
As benzyl alcohol may cross the placenta, solution for injection should be used with caution in pregnancy. Increase the central nervous system depression produced by drugs such as alcohol, general anaesthetics, hypnotics, sedatives or strong analgesics. Antagonise the action of adrenaline and other sympathomimetic agents and reverse the blood-pressure lowering effects of adrenergic-blocking agents such as guanethidine and clonidine.
Increase the effect of anticoagulants and antidepressants. Anticholinergic effects may be enhanced by anti-parkinsonian or other anticholinergic drugs. Fluphenazine is metabolised by P 2D6 and is itself an inhibitor of this drug metabolising enzyme.
The plasma concentrations and the effects of fluphenazine may therefore be increased and prolonged by drugs that are either the substrates or inhibitors of this P isoform, possibly resulting in severe hypotension, cardiac arrhythmias or CNS side effects. This list is not exhaustive.
Concomitant use of barbiturates with phenothiazines may result in reduced serum levels of both drugs, and an increased response if one of the drugs is withdrawn. The effect of fluphenazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Therefore, concurrent use of these drugs and fluphenazine is contraindicated. Examples include certain anti-arrhythmics, such as those of Class 1A such as quinidine, disopyramide and procainamide and Class III such as amiodarone and sotalol , tricyclic antidepressants such as amitriptyline ; certain tetracyclic antidepressants such as maprotiline ; certain antipsychotic medications such as phenothiazines and pimozide ; certain antihistamines such as terfenadine ; lithium, quinine, pentamidine and sparfloxacin.
Electrolyte imbalance, particularly hypokalaemia, greatly increases the risk of QT interval prolongation. Therefore, concurrent use of drugs that cause electrolyte imbalance should be avoided. Concurrent use of MAO inhibitors may increase sedation, constipation, dry mouth and hypotension.
Owing to their adrenolytic action, phenothiazines may reduce the pressor effect of adrenergic vasoconstrictors i. Phenylpropanolamine has been reported to interact with phenothiazines and cause ventricular arrhythmias. Concurrent use of phenothiazines and ACE inhibitors or angiotensin II antagonists may result in severe postural hypotension.
Concurrent use of thiazide diuretics may cause hypotension. Diuretic-induced hypokalaemia may potentiate phenothiazine-induced cardiotoxicity. Clonidine may decrease the antipsychotic activity of phenothiazines. Methyldopa increases the risk of extrapyramidal side effects with phenothiazines. The hypotensive effect of calcium channel blockers is enhanced by concurrent use of antipsychotic drugs.
Phenothiazines may predispose to metrizamide-induced seizures. Concurrent use of phenothiazines and cocaine may increase the risk of acute dystonia. There have been rare reports of acute Parkinsonism when an SSRI has been used in combination with a phenothiazine. Phenothiazines may impair the action of anti-convulsants.
Serum levels of phenytoin may be increased or decreased. Phenothiazines inhibit glucose uptake into cells, and hence may affect the interpretation of PET studies using labelled glucose.
The safety for the use of this drug during pregnancy has not been established; therefore, the possible hazards should be weighed against the potential benefits when administering this drug to pregnant patients. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.
Breast feeding is not recommended during treatment with depot fluphenazines, owing to the possibility that fluphenazine may be excreted in the breast milk. Acute dystonic reactions occur infrequently, as a rule within the first hours, although delayed reactions may occur.
In susceptible individuals they may occur after only small doses. These may include such dramatic manifestations as oculogyric crises and opisthotonos. They are rapidly relieved by intravenous administration of an anti-parkinsonian agent such as procyclidine. Parkinsonian-like states may occur particularly between the second and fifth days after each injection, but often decrease with subsequent injection.
These reactions may be reduced by using smaller doses more frequently, or by the concomitant use of antiparkinsonian drugs such as trihexyphenidyl, benzatropine or procyclidine. Antiparkinsonian drugs should not be prescribed routinely, because of the possible risks of aggravating anti-cholinergic side effects or precipitating toxic confusional states, or of impairing therapeutic efficacy.
With careful monitoring of the dose the number of patients requiring anti-parkinsonian drugs can be minimised. As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long term therapy or may occur after drug therapy has been discontinued.
The risk seems to be greater in elderly patients on high dose therapy, especially females. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterised by rhythmical involuntary movements of the tongue, face, mouth or jaw e. Sometimes these may be accompanied by involuntary movements of the extremities. There is no known effective treatment for tardive dyskinesia: It is suggested that all antipsychotic agents be discontinued if these symptoms appear.
Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked. As with other phenothiazines, drowsiness, lethargy, blurred vision, dryness of the mouth, constipation, urinary hesitancy or incontinence, mild hypotension, impairment of judgement and mental skills, and epileptiform attacks are occasionally seen.
Headache, nasal congestion, vomiting, agitation, excitement, insomnia and hyponatraemia have also been observed during phenothiazine therapy. Blood dyscrasias have rarely been reported with phenothiazine derivatives. Blood counts should be performed if the patient develops signs of persistent infection.
Transient leucopenia and thrombocytopenia have been reported. Antinuclear antibodies and SLE have been reported very rarely.